Related Experiment Video
Updated: Jul 6, 2026
07:30
HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
Published on: July 9, 2016
Schizophrenia: moving beyond monoamine antagonists
P Jeffrey Conn1, Carol Tamminga, Darryle D Schoepp
1Vanderbilt University, Department of Pharmacology, Nashville, TN 37232, USA. jeff.conn@vanderbilt.edu
Molecular Interventions
|April 12, 2008
Summary
New research explores novel treatments for schizophrenia beyond dopamine D2 receptor antagonists. Focusing on muscarinic, nicotinic, and glutamatergic pathways offers new hope for addressing negative and cognitive symptoms.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Schizophrenia is a severe psychiatric disorder with positive, negative, and cognitive symptoms.
- Early treatments focused on dopamine D2 receptor antagonists, primarily targeting positive symptoms.
- Limited efficacy of traditional antipsychotics against negative and cognitive symptoms necessitates new therapeutic strategies.
Purpose of the Study:
- To review emerging experimental approaches for schizophrenia treatment.
- To highlight the role of non-monoamine receptor targets in addressing diverse symptom clusters.
- To discuss novel drug entities and receptor subtype-specific targeting.
Main Methods:
- Review of recent neuropharmacological and behavioral studies.
- Analysis of emerging therapeutic targets beyond monoamine pathways.
- Examination of novel drug entities targeting specific receptor subtypes.
Main Results:
- New experimental approaches are identifying treatments for distinct schizophrenia symptom clusters.
- Muscarinic, nicotinic, and glutamatergic signaling are key targets for novel therapies.
- Fine-tuning pharmacological manipulation of specific receptor subtypes is advancing treatment development.
Conclusions:
- Novel therapeutic strategies targeting non-monoamine receptors show promise for schizophrenia.
- Focus on muscarinic, nicotinic, and glutamatergic systems offers potential for treating negative and cognitive symptoms.
- Precision pharmacology targeting specific receptor subtypes represents the future of schizophrenia treatment.
Related Concept Videos
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...